Hillstream Biopharma (NASDAQ:CNTN – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday, Wall Street Zen reports.
Separately, Weiss Ratings lowered Hillstream Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.
Read Our Latest Report on CNTN
Hillstream Biopharma Price Performance
CNTN stock opened at $1.71 on Friday. The firm has a market capitalization of $136.25 million, a PE ratio of -3.42 and a beta of 1.49. Hillstream Biopharma has a twelve month low of $1.66 and a twelve month high of $5.83. The stock’s 50 day moving average is $2.09 and its 200-day moving average is $2.63.
About Hillstream Biopharma
Hillstream BioPharma is a biotechnology company focused on developing experimental treatments for cancer, particularly drug-resistant tumors and cancer stem cells. Its research centers on ferroptosis, a form of cell death that may offer a way to attack cancer cells that are difficult to treat with existing therapies. The company’s development work includes its LION platform, which uses liposomal iron oxide nanoparticles to deliver iron to cancer cells and promote ferroptosis. Hillstream has described HSB-1216 as a potential cancer treatment based on this approach.
See Also
- Five stocks we like better than Hillstream Biopharma
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Hillstream Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hillstream Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
